PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-19.90%
Both companies show declining cash positions (-19.90% vs TRAW's -23.70%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-19.90%
Similar yoy growth to TRAW's -18.65%. Walter Schloss would note comparable liquidity expansions. Examine capital usage strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.69%
1.25-1.5x TRAW's -16.53%. Bruce Berkowitz checks if strong current asset growth is used effectively.
6.10%
Below half TRAW's -15.93%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRAW and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.84%
Below half of TRAW's -13.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-18.44%
1.25-1.5x TRAW's -16.49%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
65.60%
Above 1.5x TRAW's 7.12%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-100.00%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRAW and the company show zero Deferred Revenue (Current) Growth.
-13.55%
Less than half of TRAW's 29.15%. David Dodd sees fewer expansions in other current obligations.
-8.01%
Less than half of TRAW's 9.17%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.01%
Less than half of TRAW's 3.82%. David Dodd sees far fewer liability expansions relative to competitor.
7.31%
Less than half of TRAW's -100.00%. David Dodd sees fewer share issuances vs. competitor.
-7.62%
1.25-1.5x TRAW's -5.59%. Bruce Berkowitz notes stronger reinvestment strategy.
-130.04%
Higher AOCI Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-45.22%
≥ 1.5x TRAW's -27.31%. David Dodd sees stronger capital base growth than competitor.
-18.44%
1.25-1.5x TRAW's -16.49%. Bruce Berkowitz checks if expansions are well-justified by ROI.
-100.00%
Below half TRAW's 0.01%. Michael Burry suspects major underinvestment or forced divestment.
-100.00%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
19.60%
Similar yoy changes to TRAW's 23.70%. Walter Schloss sees parallel net leverage strategies.